| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 04/19/2000 | CN1051456C Process for preparing nerve growth factor |
| 04/18/2000 | US6051688 Amino acid sequence for polypeptide of at least 6 contiguous amino acids; for diagnosis and treatment of nervous system disorders; anticonvulsants; antiischemic/antihypoxic agents; antiepileptic agents; alzheimer's/parkinson's diseases |
| 04/18/2000 | US6051684 Contacting a composition containing amyloid precursor protein with di- or tripeptide analog causing a decrease in a-beta-peptide or an increase in alpha-s-amyloid precursor protein |
| 04/18/2000 | US6051610 Compounds useful as neuroprotectants, anticonvulsants, anxiolytics, analgesics, muscle relaxants or adjuvants to general anesthetics |
| 04/18/2000 | US6051583 2,3,3a,4,9,9a-hexahydro-8-hydroxy-1H-benz[f]indoles, processes for preparing them and their use as pharmaceutical compositions |
| 04/18/2000 | US6051581 Spiro-azabicyclic compounds useful in therapy |
| 04/18/2000 | US6051571 Methods for treating medical dysfunctions and diseases using furan nitrone compounds |
| 04/18/2000 | US6051564 Phosphatidic acid-comprising compositions |
| 04/18/2000 | US6051559 Cloning and characterizing of genes associated with long-term memory |
| 04/18/2000 | US6051400 An expression system comprising of a polynucleotide encoding a protein; therapy and diagnosis of kidney diseases, cardiovascular disorders, strokes, alzheimer's disease; anticarcinogenic agents and antiinflammatory agents |
| 04/18/2000 | CA2166700C Heterocyclic amines having central nervous system activity |
| 04/18/2000 | CA2087604C Diamine compounds and cerebral protective drugs containing the same |
| 04/18/2000 | CA1340964C Crf analogs |
| 04/13/2000 | WO2000020867A1 A novel ret-independent signaling pathway for gdnf |
| 04/13/2000 | WO2000020635A1 ANTISENSE MODULATION OF INTEGRIN α4 EXPRESSION |
| 04/13/2000 | WO2000020634A1 Methods for treating or identifying a subject at risk for a neurological disease by determining the presence of a variant gpiiia and/or variant gpiib allele |
| 04/13/2000 | WO2000020621A1 Extracellular novel rage binding protein (en-rage) and uses thereof |
| 04/13/2000 | WO2000020601A2 Polyketide synthase enzymes and recombinant dna constructs therefor |
| 04/13/2000 | WO2000020590A2 G-protein coupled receptor proteins |
| 04/13/2000 | WO2000020450A2 Calcium channel alpha-2/delta gene |
| 04/13/2000 | WO2000020448A2 Nlk1 -interacting proteins |
| 04/13/2000 | WO2000020447A2 Polynucleotides coding for secreted polypeptides, some having similarity to syncollin or claudin or cytokine, their therapeutic uses |
| 04/13/2000 | WO2000020444A1 Novel peptides |
| 04/13/2000 | WO2000020443A1 Novel peptides |
| 04/13/2000 | WO2000020440A1 Caspases and apoptosis |
| 04/13/2000 | WO2000020434A1 Cadherin-like asymmetry protein-1, and methods for its use |
| 04/13/2000 | WO2000020423A1 Tricyclic δ3-piperidines as pharmaceuticals |
| 04/13/2000 | WO2000020422A1 BENZOTHIENO[3,2-c]PYRIDINES AS α2 ANTAGONISTS |
| 04/13/2000 | WO2000020421A2 TRICYCLIC Δ3-PIPERIDINES AS α2-ANTAGONISTS |
| 04/13/2000 | WO2000020398A1 Biphenylene lactams as prostaglandin receptor ligands |
| 04/13/2000 | WO2000020397A1 Tetrahydroquinoline derivatives having selective activity for retinoid x receptors |
| 04/13/2000 | WO2000020390A1 Monomeric and dimeric heterocycles, and therapeutic uses thereof |
| 04/13/2000 | WO2000020389A1 Naphthalenecarboxamides as tachykinin receptor antagonists |
| 04/13/2000 | WO2000020376A1 N-aralkylaminotetralins as ligands for the neuropeptide y y5 receptor |
| 04/13/2000 | WO2000020371A1 Prostaglandin receptor ligands |
| 04/13/2000 | WO2000020370A1 2, 4-pentadienoic acid derivatives having selective activity for retinoid x (rxr) receptors |
| 04/13/2000 | WO2000020037A1 A novel component in the hedgehog signalling pathway |
| 04/13/2000 | WO2000020024A2 Methods for the treatment of non-thyroid disorders |
| 04/13/2000 | WO2000020020A2 Method for screening for anti-amyloidogenic properties and method for treatment of neurodegenerative disease |
| 04/13/2000 | WO2000020016A1 Animal stereotypy |
| 04/13/2000 | WO2000020013A1 Reduction of oxidative stress factors |
| 04/13/2000 | WO2000020011A1 Isolated dna encoding human h3 histamine receptor |
| 04/13/2000 | WO2000020003A1 Naphthalenecarboxamides as tachykinin receptor antagonists |
| 04/13/2000 | WO2000020001A1 Mglur5 antagonists for the treatment of pain and anxiety |
| 04/13/2000 | WO2000019987A1 Mucosal originated drug delivery systems and animal applications |
| 04/13/2000 | WO2000019985A2 New sustained release oral formulations |
| 04/13/2000 | WO2000002877A3 New pharmaceutically active compounds |
| 04/13/2000 | WO2000002850A3 Sulfonylamino carboxylic acid n-arylamides as guanylate cyclase activators |
| 04/13/2000 | WO2000002545A3 Compositions comprising gaba analogs and a decongestant to relieve sinus headache pain |
| 04/13/2000 | WO2000001415A3 Use of inhibitors of protein kinase c epsilon to treat pain |
| 04/13/2000 | WO1999065490A3 Use of optically pure (-) norcisapride in the treatment of apnea, bulimia, and other disorders |
| 04/13/2000 | WO1999059563A3 Cabergoline and pramipexole for treating cns diseases, especially parkinson's disease |
| 04/13/2000 | DE19842416A1 Sekundäre Amine zur Prävention und Therapie von Erkrankungen, die durch Oxidationsprozesse verursacht oder verstärkt werden Secondary amines for the prevention and treatment of diseases that are caused or aggravated by oxidation processes |
| 04/13/2000 | CA2354544A1 Methods for treating or identifying a subject at risk for a neurological disease by determining the presence of a variant gpiiia and/or variant gpiib allele |
| 04/13/2000 | CA2347120A1 Nlk1 -interacting proteins |
| 04/13/2000 | CA2346646A1 Animal stereotypy |
| 04/13/2000 | CA2346537A1 Monomeric and dimeric heterocycles, and therapeutic uses thereof |
| 04/13/2000 | CA2346445A1 Biphenylene lactams as prostaglandin receptor ligands |
| 04/13/2000 | CA2346443A1 Prostaglandin receptor ligands |
| 04/13/2000 | CA2346363A1 N-aralkylaminotetralins as ligands for the neuropeptide y y5 receptor |
| 04/13/2000 | CA2346217A1 Extracellular novel rage binding protein (en-rage) and uses thereof |
| 04/13/2000 | CA2346037A1 Tetrahydroquinoline derivatives having selective activity for retinoid x receptors |
| 04/13/2000 | CA2346034A1 2, 4-pentadienoic acid derivatives having selective activity for retinoid x (rxr) receptors |
| 04/13/2000 | CA2345808A1 Mucosal originated drug delivery systems and animal applications |
| 04/13/2000 | CA2345642A1 Methods for the treatment of non-thyroid disorders |
| 04/13/2000 | CA2345377A1 Novel secreted proteins and polynucleotides encoding them |
| 04/13/2000 | CA2345209A1 Antisense modulation of integrin .alpha.4 expression |
| 04/13/2000 | CA2345137A1 Mglur5 antagonists for the treatment of pain and anxiety |
| 04/13/2000 | CA2345133A1 Naphthalenecarboxamides as tachykinin receptor antagonists |
| 04/13/2000 | CA2345110A1 Reduction of oxidative stress factors |
| 04/13/2000 | CA2345045A1 G-protein coupled receptor proteins |
| 04/13/2000 | CA2344973A1 Oxidoreductase molecules |
| 04/13/2000 | CA2344807A1 Naphthalenecarboxamides as tachykinin receptor antagonists |
| 04/13/2000 | CA2344765A1 Novel peptides |
| 04/13/2000 | CA2344551A1 P-conotoxin peptide |
| 04/13/2000 | CA2344266A1 Cadherin-like asymmetry protein-1, and methods for its use |
| 04/13/2000 | CA2341351A1 Alpha-2/delta gene |
| 04/12/2000 | EP0992584A2 Purified mammalian FLT3 ligands and agonists and antagonists thereof |
| 04/12/2000 | EP0992493A1 Substituted benzoylpiperidine derivatives and their use as Neurokinin antagonists |
| 04/12/2000 | EP0992492A1 Small molecule inhibitors of rotamase enzyme activity |
| 04/12/2000 | EP0991771A2 Lentivirus based vector and vector system |
| 04/12/2000 | EP0991654A1 Novel 2-(iminomethyl)amino-phenyl derivatives, preparation, application as medicines and compositions containing same |
| 04/12/2000 | EP0991652A1 Tricyclic pyrazolo-pyridazinone analogues as gaba-a receptor ligands |
| 04/12/2000 | EP0991650A1 Novel n-benzenesulphonyl-l-proline compounds, preparation method and use in therapy |
| 04/12/2000 | EP0991642A1 2-aminoalkylaminoquinolines as dopamine d4 ligands |
| 04/12/2000 | EP0991622A1 Substituted 3-(benzylamino)piperidine derivatives and their use as therapeutic agents |
| 04/12/2000 | EP0991618A1 Selective thyroid hormone analogs |
| 04/12/2000 | EP0991614A1 Synthesis of dihydrohonokiol compositions |
| 04/12/2000 | EP0991424A1 Pharmaceutical compositions comprising an aldose reductase inhibitor and an ace inhibitor |
| 04/12/2000 | EP0991409A1 Controlled release pharmaceutical compositions containing tiagabine |
| 04/12/2000 | EP0991408A1 Novel process for manufacturing paroxetine solid dispersions |
| 04/12/2000 | CN1250480A Eukaryotic gene expression cassette and uses thereof |
| 04/12/2000 | CN1250444A 1-phenyl-4-benzylpiperazines: dopamine receptor subtype specific ligands (D4) |
| 04/12/2000 | CN1250051A New indane-1-alcohol compound, its preparation method and medical composition containing the same |
| 04/12/2000 | CN1051313C 5-arylindole derivatives and its use, pharmaceutical composition containing the same and intermediate for preparing them |
| 04/12/2000 | CN1051308C Oxazolidin-2-one derivatives and medicine containing the same |
| 04/12/2000 | CN1051302C 3-(indol-3-yL) propenoic acid derivatives and as NMDA antagonists |
| 04/12/2000 | CN1051240C Hypnotic health bath lotion containing chinese medicine |
| 04/12/2000 | CN1051237C Medicine for treating epiplepsy |
| 04/12/2000 | CN1051226C Preparation of medicine for treating imbalance of memory and recognition with tri-cyclic compound |